In the past week, ITOS stock has gone down by -7.09%, with a monthly decline of -11.19% and a quarterly plunge of -55.03%. The volatility ratio for the week is 6.60%, and the volatility levels for the last 30 days are 5.91% for ITeos Therapeutics Inc. The simple moving average for the past 20 days is -9.50% for ITOS’s stock, with a -39.79% simple moving average for the past 200 days.
Is It Worth Investing in ITeos Therapeutics Inc (NASDAQ: ITOS) Right Now?
The 36-month beta value for ITOS is also noteworthy at 1.37. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ITOS is 28.81M, and at present, short sellers hold a 10.83% of that float. The average trading volume of ITOS on November 21, 2024 was 683.92K shares.
ITOS) stock’s latest price update
ITeos Therapeutics Inc (NASDAQ: ITOS)’s stock price has gone rise by 0.13 in comparison to its previous close of 7.85, however, the company has experienced a -7.09% decrease in its stock price over the last five trading days. globenewswire.com reported 2024-11-12 that – EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU – Interim data from inupadenant Phase 2 A2A-005 in 2L NSCLC at ESMO-IO – Completed enrollment of EOS-984 Phase 1 monotherapy dose escalation and initiated dosing of EOS-984 + pembrolizumab combination – Pro forma cash and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 across a number of impactful portfolio milestones
Analysts’ Opinion of ITOS
Many brokerage firms have already submitted their reports for ITOS stocks, with Wells Fargo repeating the rating for ITOS by listing it as a “Overweight.” The predicted price for ITOS in the upcoming period, according to Wells Fargo is $31 based on the research report published on August 13, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ITOS reach a price target of $37. The rating they have provided for ITOS stocks is “Buy” according to the report published on May 05th, 2021.
Robert W. Baird gave a rating of “Outperform” to ITOS, setting the target price at $45 in the report published on October 08th of the previous year.
ITOS Trading at -18.23% from the 50-Day Moving Average
After a stumble in the market that brought ITOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.08% of loss for the given period.
Volatility was left at 5.91%, however, over the last 30 days, the volatility rate increased by 6.60%, as shares sank -9.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -53.91% lower at present.
During the last 5 trading sessions, ITOS fell by -7.92%, which changed the moving average for the period of 200-days by -22.18% in comparison to the 20-day moving average, which settled at $8.68. In addition, ITeos Therapeutics Inc saw -28.22% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ITOS starting from Gall Matthew, who purchase 5,000 shares at the price of $7.73 back on Nov 19 ’24. After this action, Gall Matthew now owns 65,429 shares of ITeos Therapeutics Inc, valued at $38,635 using the latest closing price.
Stock Fundamentals for ITOS
Current profitability levels for the company are sitting at:
- -6.34 for the present operating margin
- 0.96 for the gross margin
The net margin for ITeos Therapeutics Inc stands at -5.12. The total capital return value is set at -0.22. Equity return is now at value -19.72, with -17.31 for asset returns.
Currently, EBITDA for the company is -151.1 million with net debt to EBITDA at 0.85. When we switch over and look at the enterprise to sales, we see a ratio of 7.31. The receivables turnover for the company is 0.55for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.80.
Conclusion
In summary, ITeos Therapeutics Inc (ITOS) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
